The quest for personalized B-cell depletion therapy in rheumatic disease

Although B cell depletion therapy (BCDT) is now a well-accepted therapeutic option in autoimmune rheumatic disease, a significant proportion of patients remain resistant to therapy. .19pt?>A more challenging clinical problem is the high rate of relapse after B cell reconstitution, as well as the...

Full description

Saved in:
Bibliographic Details
Published inArthritis research & therapy Vol. 16; no. 3; p. 116
Main Authors Nistala, Kiran, Mauri, Claudia
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 01.01.2014
BioMed Central
Subjects
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Antirheumatic Agents - therapeutic use
Autoantibodies - blood
Autoantibodies - immunology
B-Lymphocyte Subsets - immunology
B-Lymphocyte Subsets - metabolism
Humans
Lymphocyte Depletion - methods
Rheumatic Diseases - blood
Rheumatic Diseases - drug therapy
Rheumatic Diseases - immunology
Rituximab
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:Although B cell depletion therapy (BCDT) is now a well-accepted therapeutic option in autoimmune rheumatic disease, a significant proportion of patients remain resistant to therapy. .19pt?>A more challenging clinical problem is the high rate of relapse after B cell reconstitution, as well as the difficulty in predicting the exact timing of that relapse. In this article, we consider the immunological mechanisms that may account for the heterogeneity of clinical response to BCDT. Understanding how BCDT alters the balance between different B cell subsets, some pathogenic and some regulatory, may help us correctly target BCDT to the right patients, and thereby improve treatment responses in rheumatic disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1478-6354
1478-6362
1478-6354
DOI:10.1186/ar4595